Unknown

Dataset Information

0

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers.


ABSTRACT:

Purpose

Aromatase inhibitor (AI) treatment is the standard of care for postmenopausal women with primary estrogen receptor-positive breast cancer. The impact of duration of neoadjuvant endocrine therapy (NET) on molecular characteristics is still unknown. We evaluated and compared changes of gene expression profiles under short-term (2-week) versus longer-term neoadjuvant AIs.

Experimental design

Global gene expression profiles from the PeriOperative Endocrine Therapy for Individualised Care (POETIC) trial (137 received 2 weeks of AIs and 47 received no treatment) and targeted gene expression from 80 patients with breast cancer treated with NET for more than 1 month (NeoAI) were assessed. Intrinsic subtyping, module scores covering different cancer pathways and immune-related genes were calculated for pretreated and posttreated tumors.

Results

The differences in intrinsic subtypes after NET were comparable between the two cohorts, with most Luminal B (90.0% in the POETIC trial and 76.3% in NeoAI) and 50.0% of HER2 enriched at baseline reclassified as Luminal A or normal-like after NET. Downregulation of proliferative-related pathways was observed after 2 weeks of AIs. However, more changes in genes from cancer-signaling pathways such as MAPK and PI3K/AKT/mTOR and immune response/immune-checkpoint components that were associated with AI-resistant tumors and differential outcome were observed in the NeoAI study.

Conclusions

Tumor transcriptional profiles undergo bigger changes in response to longer NET. Changes in HER2-enriched and Luminal B subtypes are similar between the two cohorts, thus AI-sensitive intrinsic subtype tumors associated with good survival might be identified after 2 weeks of AI. The changes of immune-checkpoint component expression in early AI resistance and its impact on survival outcome warrants careful investigation in clinical trials.

SUBMITTER: Bergamino MA 

PROVIDER: S-EPMC7612503 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4980485 | biostudies-literature
| S-EPMC6454890 | biostudies-literature
| S-EPMC3059257 | biostudies-literature
| S-EPMC3933249 | biostudies-literature
| S-EPMC10177097 | biostudies-literature
| S-EPMC6933697 | biostudies-literature
| S-EPMC3686594 | biostudies-literature
| S-EPMC9652412 | biostudies-literature
| S-EPMC7238733 | biostudies-literature
| S-EPMC6964139 | biostudies-literature